SBFM (Sunshine Biopharma) has seen one of the most dramatic lending-market dislocations in its history. In five trading days, the cost to borrow exploded from 17% to 561%. Short interest jumped 603% in a week to 13.6% of free float.
A week ago, the borrow market was wide open. Availability stood at 1,295% — roughly 13 shares available for every one already borrowed. That changed violently after a May 13 earnings print that sent the stock down 55% in a single session.
Short sellers piled in. Availability collapsed to 3.3% by May 15 — the tightest reading recorded over the past 52 weeks. As of May 18, availability has partially recovered to 28%, but the lending market remains extremely tight by any standard.
Cost to borrow tells the same story. The rate held near 17–19% for months. On May 18, it printed 561% — a 3,068% weekly jump and the highest level ORTEX has recorded for this stock.
The ORTEX short score hit 80.1 on May 15, up from 46 just one week earlier. The utilization rank sits in the 2nd percentile. The short score rank is in the 4th percentile. Both figures confirm extreme short-side pressure relative to the broader market.
Short interest in absolute terms remains modest — roughly 666,000 shares — but the pace of build is what stands out. Positions were near 82,000 shares on May 12. They more than doubled by May 14, then nearly doubled again by May 15.
An earnings event is scheduled for May 20. The stock already dropped 55% on the May 13 print. It briefly rebounded 79% on May 18 — volatility that illustrates how thin and reactive the float is.
Availability remains tight at 28%. New short positions will be expensive to establish at 561% cost to borrow. That rate also creates daily carry pressure on existing shorts.
Data summary
See the live data behind this article on ORTEX.
Open SBFM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
